◈Domain Discovery

Cognition & Neuroprotection

Targets involved in synaptic plasticity, neurogenesis, and neurodegeneration. Compounds are ranked by target influence (IDF-weighted), research rarity, and momentum — revealing under-studied candidates with active signal.

Targets:NTRK2MAPTAPPBACE1ACHECHRM1DRD2HTR2AGRIN2BMAPK8GSK3BPSEN1SLC6A4SLC6A3

399 compounds matched · 14 targets active

Top Emerging Cognition & Neuroprotection Compounds

#	Compound	Top Targets	Score	Studies
1	egcgcap⚡	BACE1 · GSK3B · APP	19.262	300
2	fisetin⚡	GSK3B · MAPT · ACHE	16.369	78
3	Rutincap⚡	BACE1 · GSK3B · ACHE	14.446	300
4	Fluoxetinecap⚡	SLC6A4 · ACHE · SLC6A3	14.352	1,000
5	Mianserin⚡	SLC6A4 · DRD2 · HTR2A	13.021	299
6	Duloxetine Hydrochloridecap⚡	SLC6A4 · SLC6A3 · DRD2	9.422	993
7	Luteolin 5,7,3',4'-tetrahydroxy-flavone,	BACE1 · GSK3B · APP	8.683	150
8	Quercetincap	BACE1 · GSK3B · APP	7.653	300
9	Amlodipinecap⚡	SLC6A3 · DRD2 · CHRM1	6.779	1,000
10	myricetin-3-O-galactopyranoside [Supplementary Concept]cap	BACE1 · APP · MAPT	5.974	300

Sort

Min targets

Target

Under-cap onlyAccelerating ⚡50 compounds

#	Compound	Targets	Score	Studies	Evid.
1	egcgcap⚡ 1% human	BACE1GSK3BAPPMAPT	19.262	300	43.2
2	fisetin⚡	GSK3BMAPTACHE	16.369	78	42.5
3	Rutincap⚡ 2% human	BACE1GSK3BACHE	14.446	300	41.5
4	Fluoxetinecap⚡ 42% human	SLC6A4ACHESLC6A3DRD2+1	14.352	1,000	73.4
5	Mianserin⚡ 20% human	SLC6A4DRD2HTR2ACHRM1	13.021	299	47.8
6	Duloxetine Hydrochloridecap⚡ 40% human	SLC6A4SLC6A3DRD2HTR2A	9.422	993	70.7
7	Luteolin 5,7,3',4'-tetrahydroxy-flavone, 1% human	BACE1GSK3BAPPMAPT+1	8.683	150	40.6
8	Quercetincap 1% human	BACE1GSK3BAPPMAPT+1	7.653	300	43.4
9	Amlodipinecap⚡ 60% human	SLC6A3DRD2CHRM1	6.779	1,000	76
10	myricetin-3-O-galactopyranoside [Supplementary Concept]cap 0% human	BACE1APPMAPTACHE	5.974	300	42.3
11	Sertralinecap⚡ 46% human	SLC6A4SLC6A3CHRM1	5.730	1,000	74.3
12	propionylpromazine hydrochloride	DRD2HTR2ACHRM1	5.707	2	9.6
13	Kaempferolscap	GSK3BAPPMAPTCHRM1	5.523	300	43.3
14	mg624	ACHEHTR2ACHRM1	5.375	3	17.7
15	chrysincap⚡ 0% human	GSK3B	5.037	300	39.8
16	chlorprothixene hydrochloride	DRD2CHRM1	4.475	1	4.9
17	Escitalopram S-enantiomer of CITALOPRAM. Belongs tocap 43% human	SLC6A4SLC6A3CHRM1	4.301	995	73
18	agmatine⚡ 3% human	MAPT	4.233	177	43.8
19	tyrphostin 9	MAPTCHRM1	4.213	2	11.5
20	Chlorhexidine 2% human	MAPTSLC6A4ACHESLC6A3+3	4.040	299	43.4
21	Metergoline 12% human	SLC6A4ACHESLC6A3DRD2+2	3.889	144	46.3
22	pirenperone	ACHEDRD2HTR2ACHRM1	3.858	22	30.1
23	Apigenin 5,7,4'-trihydroxy-flavone,cap	BACE1GSK3BAPPMAPT+1	3.827	300	42.3
24	aniracetam⚡ 9% human	DRD2	3.815	110	46.1
25	ethopropazine hydrochloride	HTR2ACHRM1	3.771	2	7.6

score = target_influence × rarity × momentum⚡ acceleration >2×cap = ≥300 studies (corpus ceiling)click target chip to filter

About Cognition & Neuroprotection Compound Discovery

Discover emerging nootropic and neuroprotective compounds via BDNF, GSK3B, BACE1, and acetylcholinesterase target networks. The discovery score combines three signals: target influence (how strongly a substance interacts with cognition & neuroprotection targets, weighted by target specificity via IDF), rarity factor (inverse log of study count — fewer studies means higher discovery potential), and momentum factor (recent publication acceleration). Compounds with high scores represent mechanistically relevant, under-researched candidates with active research interest.

Key targets in this domain include: BDNF, NTRK2, MAPT, APP, BACE1, ACHE. The analysis covers 399 compounds from the BiohacksAI corpus of 4,824 substances derived from PubMed-indexed bioassay data.